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Abstract
Background—Efavirenz has been a mainstay of antiretroviral therapy (ART) for over 15 years 
in the US. Its association with neuropsychiatric side effects may influence clinical prescribing and 
management.
Methods—We included HIV-infected adults enrolled in care at 7 sites across the US, who 
initiated combination ART between 1999 and 2015. We examined the proportion initiating and 
continuing on efavirenz, overall and by mental health status. Log binomial and Cox models were 
used to estimate associations between mental health, clinical, and sociodemographic 
characteristics and initiating or switching from efavirenz as first line ART.
Results—Of the 8,230 participants included, 3,710 (45%) initiated efavirenz. In multivariable 
analyses, prior mono or dual ART, ART initiation after 2006, being female, intravenous drug use, 
*Corresponding author angela_bengtson@brown.edu. 
Presentation
A version of this work was presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, Washington, 
February 13-16, 2017.
Conflicts of Interest
KM has received research support from grants awarded to UNC from Merck, AbbVie, and Gilead. All other authors have no conflicts 
of interest to report.
HHS Public Access
Author manuscript
Antivir Ther. Author manuscript; available in PMC 2019 January 01.
Published in final edited form as:













antidepressant prescription, previous mental health diagnosis and baseline CD4 >350 were 
inversely associated with initiating efavirenz. Participants initiating efavirenz had a faster time to a 
regimen switch, compared to those initiating an efavirenz-free regimen (p-value <0.01). Among 
efavirenz initiators, starting efavirenz in more recent time-periods and a previous mental health 
diagnosis were associated with faster time to switching from efavirenz. Despite this, 40–50% of 
participants with a previous mental health diagnosis initiated and continued on efavirenz for much 
of the follow-up period.
Conclusions—Multiple clinical factors, including mental health diagnoses, appeared to 
influence efavirenz use. While mental health diagnosis status and more recent treatment starts 
were associated with shorter duration of efavirenz therapy, a previous mental health diagnosis did 
not preclude efavirenz initiation or continuation in many participants.
Introduction
For over 15 years, efavirenz has been a central component of antiretroviral therapy (ART) in 
the United States (US)(1, 2) and continues to be recommended by the World Health 
Organization (WHO) globally.(3, 4) Until 2014, a 600 mg dose of efavirenz (hereafter 
‘efavirenz’) was a preferred first line antiretroviral (ARV) agent in the US due to its durable 
viral suppression, generic formulation, and availability as a fixed-dose combination pill.(1) 
Efavirenz continues to be widely taken by HIV-infected adults in the US, and remains a 
preferred first line agent for millions of HIV-infected persons in low and middle-income 
countries.(5–9)
Despite efavirenz’s desirable treatment qualities, it has been associated with important 
neuropsychiatric side effects including mood changes, sleep disturbances, and depression.(5, 
10, 11) Evidence about severe side effects, such as suicidal thoughts or suicide, remains 
conflicting (11–16). As a result, clinicians have faced challenging questions about whether 
to prescribe efavirenz to patients with mental health diagnoses or to switch patients who 
develop mental health diagnoses from efavirenz(10) For patients already on efavirenz, 
clinicians face difficult choices about whether to continue efavirenz or to switch patients to 
newer agents, regardless of clinically evident neuropsychiatric side effects. Given these 
concerns, a clear understanding of factors associated with initiating and switching from 
efavirenz in needed.
The goal of our analysis was to examine trends in efavirenz initiation in a large cohort of 
HIV-infected adults, during the time-period when efavirenz was recommended and widely 
used for first-line combination ART in the US. We examine temporal trends in efavirenz use, 
as well as whether clinical, sociodemographic, and mental health factors influenced 
efavirenz prescription or continuation during an evolving ART treatment era from 1999–
2015.
Methods
Data for the present analysis come from the Centers for AIDS Research (CFAR) Network of 
Integrated Clinical Systems (CNICS) cohort. The CNICS cohort includes over 32,000 HIV-
infected adults in routine HIV clinical care at 8 academic medical centers across the US.(17) 
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Many patients receiving care at the sites participating in CNICs access ART at no charge or 
low cost through private or federal insurance programs, or through state administered federal 
assistance programs, such as the Ryan White Program. Since 1997, CNICS collects detailed 
information on demographic characteristics, medication prescriptions, HIV/AIDS clinical 
events, ART prescription, co-morbid conditions, CD4 count, viral load and vital status on 
patients who consent to participate. In 2005 participants in CNICS also began completing 
self-administered questionnaires, called Patient-Reported Outcomes (PROs), on touch-
screen tablets or personal computers every 4–6 months as part of routine clinical visits. 
Patients receiving care at each CNICS site provide written informed consent to participate in 
CNICS and participation is near universal.(18) Ethical approval for the use of routinely 
collected clinical data was provided by the institutional review board at each CNICS site.
Study Population
Efavirenz was recommended as part of first-line therapy by the Department of Health and 
Human Services in the US from 1999 to 2014.(2) To cover this period and the year that 
guidelines changed in the US, we included participants in CNICS who initiated combination 
ART between 1999 and 2015 (n=9,796) at 7 of 8 sites where PROs were collected.(1) A 
combination ART (hereafter ART) regimen was defined as treatment with at least 3 
antiretroviral drugs, including at least 1 non-nucleoside reverse transcriptase inhibitor, 
protease inhibitor, or integrase inhibitor for > 21 days.(19) Participants with incomplete data 
on ART use (n=517), a missing (n=623) or undetectable viral load (defined as < 75 
copies/mL) at ART initiation (n=426, possibly indicating possible previous ART treatment) 
were excluded for a final study population of 8,230. We followed participants from ART 
initiation until the first of the following dates: a switch from their initial regimen (defined as 
switching to an efavirenz-containing or efavirenz-free regimen, depending on initial ART 
regimen), discontinuing ART entirely, death, loss to care (>12 months with no attended HIV 
appointments), or administrative censoring (October 2014-September 2015, depending on 
site).
Among people who initiated efavirenz, we identified a sub-population who had a PRO at 
least 1 week after and within 9 months of ART initiation and who were still on efavirenz at 
the time of the PRO measurement (n=523). In this sub-population, we evaluated associations 
between baseline and time-updated characteristics (measured on the PRO) and switching 
from an initial efavirenz-containing regimen.
Measures
CNICS systematically collects information on demographics, prior mono or dual ARV use, 
antidepressant medication prescription, HIV acquisition risk group (male-to-male sexual 
contact [MSM], intravenous drug use [IDU], heterosexual contact, or other), previous chart-
documented mental health diagnoses or chart-documented medical diagnoses (such as 
hypertension or diabetes), CD4 count and viral load lab values. We defined a pervious 
mental health diagnosis as any clinician-documented diagnosis of depression, bipolar 
disorder, post-traumatic stress disorder or psychosis in a participant’s medical chart, since 
many of these conditions are associated with efavirenz use and may influence efavirenz 
prescription.(20, 21)
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Among the sub-population of who participants who initiated efavirenz after PRO collection 
began, CNICS PRO’s also capture validated measures of depressive symptoms (Patient 
Health Questionnaire-9, defined as a score ≥10),(22) panic disorder (Patient Health 
Questionnaire-5, defined as no panic symptoms, some panic symptoms or panic disorder),
(23) high risk alcohol use (Alcohol Use Disorders Identification Test (AUDIT-C), defined as 
an AUDIT-C score ≥ 4 for males and ≥ 3 for females),(24), current, past or no illicit drug 
use, including cocaine/crack, heroin/opiates, crystal/amphetamine use, but excluding 
marijuana (The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), 
defined as past, current or no drug use)(25, 26) and ART adherence (AIDS Clinical Trials 
Unit-4 Visual Analog Scale, defined as no missed doses in the past week (27, 28)).
Statistical Analysis
The goal of the present analysis was to describe trends in initial efavirenz prescription and 
continuation over time in the US and to identify associations between sociodemographic, 
clinical, and mental health characteristic and initiating or switching from efavirenz as first 
line ART. To investigate trends in efavirenz prescription, we examined the proportion of new 
ART users initiating efavirenz-containing ART, as well as the net proportion (defined as the 
cumulative proportion of persons who initiated efavirenz after subtracting out censored 
participants) of individuals on efavirenz during the follow-up period. Since a provider’s 
decision to prescribe efavirenz may be influenced by a patient’s mental health status, we 
also stratified the proportion of participants initiating efavirenz and the net proportion of 
participants on efavirenz each year by previous mental health diagnosis status at ART 
initiation.
Among all participants, we used log binomial models to estimate prevalence ratios (PR) for 
associations between baseline (collected at ART initiation) demographic, mental health, and 
clinical factors and initiating efavirenz-containing ART. We used the compliment of 
unadjusted Kaplan-Meier survival curves to estimate time from ART initiation to initial 
regimen switch among all participants, stratified by initial ART regimen (efavirenz-
containing versus efavirenz-free).
Among participants initiating efavirenz-containing ART, we used Cox proportional hazards 
models to examine associations between baseline characteristics and time to switching from 
an efavirenz-containing regimen. In a secondary analysis including participants who initiated 
efavirenz after PRO collection began, we included both baseline and time-updated predictors 
for switching from an efavirenz-containing regimen. The values for all time-updated 
characteristics were carried forward until the next PRO measurement. Median depression 
score values over time, measured using the PHQ-9 and modeled using restricted splines, 
were compared between participants who continued on efavirenz and those who switched 
from efavirenz. Patient characteristics between participants who initiated efavirenz in the 
primary study population (n=3,170) and the subset who initiated efavirenz after PRO 
collection began (n=523) were compared using chi-squared tests.
Due to model convergence issues, the “other” categories for HIV acquisition risk group and 
race/ethnicity was collapsed with the largest category for each variable in statistical 
analyses. Given the strong time-trends in efavirenz prescription, year of ART initiation was 
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included as a covariate in all analyses. For all analyses, characteristics with a Wald p-value 
of ≤ 0.10 in bivariable analyses were included in the multivariable model. Statistical 
analyses were conducted using Stata version 13 (StataCorp, College Station, Texas).
Results
In total, 8,230 CNICS participants with a detectable viral load initiated ART between 1999 
and 2015. Of those, 3,710 (45%) initiated an efavirenz-containing regimen. Of the 3,710 
who started EFV-containing ART, 685 (18%) switched from their initial efavirenz regimen 
and 3,025 (82%) continued on efavirenz until a censoring event or the end of follow-up. 
Over the follow-up period, 31% overall were lost to care, 4% died, 12% switched from their 
initial ART regimen, 22% discontinued ART entirely, and 31% were administratively 
censored. Participants who were lost to care were similar to those who were not, with the 
exceptions of being more likely to have initiated ART later (during 2012–2015) and less 
likely to have contracted HIV through male-to-male sexual contact (Supplemental Table 1). 
Participants were followed for a median of 24 months and contributed a total of 293,168 
person-months of follow-up.
Our study population was predominately male (83%), white, non-Hispanic (44%) and self-
reported contracting HIV through male-to-male sexual contact (57%). Nearly 16% of 
participants had an antidepressant prescription at ART initiation and 25% had a prior 
clinician-documented mental health diagnosis. The majority of the study population (68%) 
had a CD4 count ≤ 350 cells/mm3 at ART initiation (Table 1).
Efavirenz prescription for first-line ART was common during the study period. Between 
1999 and 2006, 40% – 50% of participants initiating ART started on an efavirenz-containing 
regimen (Figure 1a). Efavirenz prescription peaked in 2007 at 65% of all new ART users and 
declined rapidly thereafter. By 2014, the last year the Department of Health and Human 
Services recommended efavirenz as a part of first-line therapy, just 7% of those initiating 
ART in our study population started on efavirenz.
Throughout the study period, persons with a previous mental health diagnosis at ART 
initiation were approximately 10–15% less likely to initiate efavirenz-containing ART, 
compared to other participants (Figure 1b and 1c). However, the net proportion of 
participants who continued on efavirenz-containing ART remained high over the follow-up 
period, regardless of previous mental health diagnoses status (Supplemental Figure 1). 
Among participants with no previous mental health diagnoses, roughly 50% or more of 
participants were on efavirenz-containing ART through 2014, when the overall net 
proportion of participants on efavirenz began declining due to the fact that some patients 
reached the end of their follow-up time (e.g. they were administratively censored). By the 
end of follow-up in 2015, approximately 20% of participants with no previous mental health 
diagnoses remained on efavirenz-containing ART (Supplemental Figure 1a). Among those 
with a previous mental health diagnosis, the proportion of participants on an efavirenz-
containing regimen was lower, but remained between 40% and 50% for much of the follow-
up period. In 2015, approximately 16% of participants with previous mental health 
diagnoses remained on efavirenz (Supplemental Figure 1b).
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In multivariable analyses, baseline factors inversely associated with initiating efavirenz as 
first line ART included: prior mono or dual ARV (PR 0.78, 95% CI 0.68, 0.89), initiating 
ART from 2007–2015 (PR 0.95, 95% CI 0.90, 0.99), contracting HIV through IDU (PR 
0.85, 95% CI 0.79, 0.92), being on antidepressants (PR 0.91, 95% CI 0.84, 0.98), having a 
previous mental health diagnosis (PR 0.80, 95% CI 0.75, 0.86), being female (PR 0.80, 95% 
CI 0.74, 0.87), and having a CD4 count >350 (PR 0.94, 95% CI 0.89, 0.99) (Table 2). The 
effect of gender on efavirenz initiation was primarily driven by the fact that women of 
childbearing age (ages 15–44) were less likely to initiate efavirenz (PR 0.71, 95% CI 0.64, 
0.78), compared to older women (ages ≥ 45; PR 0.92, 95% CI 0.81, 1.03). Similarly, the 
association between CD4 count >350 and efavirenz initiation was most prominent for 
participants initiating ART between 2007 and 2015 (PR 0.89, 95% CI 0.97, 1.17), compared 
to between 1995 and 2006 (PR 1.06, 95% CI 0.97, 1.17).
Among all study participants (n=8,230), initiating efavirenz was associated with a faster 
time to switching from one’s initial ART regimen (log-rank p-value <0.01; Figure 2). For 
example, by 96 months after ART initiation, persons who initiated an efavirenz-containing 
regimen had a 34% (95% CI 31%, 37%) probability of switching, compared to 17% (95% 
CI 14% to 20%) among those who initiated an efavirenz-free regimen.
Among all participants who initiated efavirenz (n=3170), baseline factors associated with 
switching from efavirenz in multivariable analyses included initiating efavirenz from 2007–
2011 (HR 1.70, 95% CI 1.40, 2.05) or 2012–2015 (HR 3.68, 95% CI 2.93, 4.62), and having 
a previous mental health diagnosis (HR 1.33, 95% CI 1.11, 1.59; Table 3).
Of the 523 persons who initiated efavirenz after PRO collection began, 140 (27%) switched 
from their initial efavirenz regimen. Over one fifth (22%) of switches happened within 7 
days of a PRO measurement, providing a reasonable measure of the psychiatric symptoms 
present at the time of the switch, and 25% within 30 days. In multivariable analyses, time-
updated depressive symptoms (HR 1.62, 95% CI 1.01, 2.57) and ART non-adherence (HR 
1.62, 95% CI 1.01, 2.61) were associated with faster time to switching from an efavirenz-
containing regimen (Supplemental Table 2). Median PHQ-9 scores for depressive severity 
were higher among participants who eventually switched from efavirenz, compared to those 
who continued on efavirenz during the study period, but remained below the level indicating 
depressive symptoms (Supplemental Figure 2). Participants who initiated efavirenz after 
PRO collection began, compared to efavirenz initiators in the entire study population, were 
more likely to switch from their initial regimen (27% versus 19%), but less likely to 
discontinue ART entirely (6% versus 20%, combined p-value <0.01), and were more likely 
to be male (92% versus 86%, p-value <0.01), MSM (75% versus 61%, p-value <0.01), and 
to have a CD4 count at ART initiation >350 cells/mm3 (42% versus 30%, p-value <0.01; 
Supplemental Table 3).
Discussion
Our analysis examines efavirenz use among a large cohort of HIV-infected adults during the 
15 years it was recommended as first-line ART in the US. After its introduction in 1999, 
efavirenz use expanded rapidly in our cohort reaching its peak in 2007 when 60% of 
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treatment naïve participants were initiated on efavirenz-containing ART. Between 1999 and 
2015, patients with a previous mental health diagnosis were less likely to be prescribed 
efavirenz as initial therapy and more likely to switch from an initial efavirenz-containing 
regimen. Despite this, efavirenz initiation was relatively common among people with 
previous mental health diagnoses. Through 2011, over 30% of patients with a previous 
mental health diagnosis initiated efavirenz-containing ART each year and 40–50% of this 
population continued on the drug. Over the study period, participants initiating efavirenz 
were more likely to switch from their initial regimen, compared with participants initiating 
an efavirenz-free regimen.
Efavirenz has been associated with a range of adverse mental health outcomes, including 
mood changes, insomnia, depression and suicidal thoughts.(5, 10) Our results demonstrate 
that patients with mental health concerns were less likely to be prescribed efavirenz as initial 
ART. In multivariable analyses those with an antidepressant prescription or a previous 
mental health diagnosis at ART initiation, as well as women, IDUs, those previously on 
mono or dual ARVs, those with a CD4 count >350, and those starting ART after 2006 were 
all less likely to initiate efavirenz-containing ART. IDUs may have been less likely to be 
prescribed efavirenz due to concerns about adherence and efavirenz low genetic barrier to 
resistance. (29) HIV-infected women have been reported to have a higher prevalence of 
depression, compared to HIV-infected men (30), which may influence efavirenz 
prescription. However, concerns about teratogenicity with efavirenz use (31–33) also likely 
led to fewer women of childbearing age initiating efavirenz. Participants with a CD4 count 
>350 were less likely to initiate efavirenz after 2007, when integrase inhibitors became 
available, possibly reflecting a clinical preference for prescribing newer or alternative 
agents.(34, 35)
Among participants who initiated efavirenz, mental health status, ART initiation after 2006, 
depressive symptoms and poor ART adherence were associated with switching off the drug. 
By 2006, there was a growing body of evidence reporting associations between efavirenz 
and mental health side effects.(36, 37) In addition, integrase inhibitors, which have superior 
viral suppression and fewer side effects than efavirenz, became available in 2007 and were 
quickly adopted by clinicians as the preferred choice for first-line therapy.(38, 39) Concerns 
over efavirenz’s influence on mental health side effects, coupled with the availability of 
alternative agents, including some single tablet regimens, may have influenced patient and 
provider decision-making related to ART prescriptions. Indeed, our results demonstrate a 
shorter time to switching from efavirenz in those who initiated ART after 2006 and those 
who had a previous mental health diagnosis at ART initiation. Similarly, among those who 
initiated efavirenz in the PRO era, patients who reported depressive symptoms and who 
missed ART doses over time, possibly due to side effects, were more likely to switch from 
efavirenz. Over time, depressive symptom scores were higher among participants who 
switched from efavirenz, compared to those who continued on efavirenz throughout the 
study period, but remained below the threshold indicated depressive symptoms.
While mental health factors led to switching from efavirenz in some patients, our results also 
demonstrate that 40–50% of participants with a previous mental health diagnosis at ART 
initiation successfully remained on efavirenz for much of the follow-up period. These 
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disparate results suggest that while some patients initiate efavirenz and develop mental 
health side effects necessitating a regimen change, other patients, including some with a 
history of mental health diagnoses, do well on the drug. Provider practices around when to 
switch a patient’s ART regimen also vary and may be strongly influenced by the availability 
of alternative ART agents.(34, 40) Indeed, our results suggest that the presence of 
psychiatric symptoms on PRO measures did not drive decisions about switching from 
efavirenz – just 22% of switches occurred within 7 days of a PRO measure and 25% 
occurred within 30 days.
Our analysis had several limitations. First, while our analysis makes use of one of the largest 
clinical cohorts of HIV-infected adults in the US, white males made up the majority of our 
cohort. We had limited data on patients who completed PRO measures (including time-
updated measures of depressive symptoms, panic disorder, and antidepressant use) over 
time. Further, the subset of participants with PRO measures differed in several important 
ways from the larger cohort. Second, despite examining a range of clinical, 
sociodemographic, and mental health characteristics, we did not have data on the cost of 
individual drugs, drug side effects not related to mental health, or a patient’s provider, all of 
which may have influenced efavirenz prescription and switching patterns. Similarly, data on 
reasons for regimen switch, discontinuation, or provider attitudes towards efavirenz use are 
not available in our data.
Conclusions
In our cohort of HIV-infected adults initiating ART between 1999 and 2015, a variety of 
factors, including mental health status and antidepressant use, influenced the likelihood of 
being prescribed or switching from efavirenz as first line ART. Our results corroborate 
previous evidence showing that clinicians are often hesitant to prescribe efavirenz to persons 
with mental health diagnoses, and may switch participants more quickly with mental health 
diagnoses from efavirenz, due to its association with neuropsychiatric side effects.(5, 10) 
However, our results also demonstrate that a sizeable proportion of participants, including 
those with previous mental health diagnoses, initiated efavirenz and successfully continued 
on the drug during the study period. Taken together, these results suggest that for patients on 
efavirenz who are virally suppressed and monitored for ongoing neuropsychiatric side 
effects, the benefits of remaining on a stable regimen may outweigh possible risks of 
developing neuropsychiatric side effects or new toxicities associated with switching to a 
different regimen. For example, some newer agents, such as dolutegravir, have also been 
associated with neuro-psychiatric side-effects.(41–44) Additional data is needed on mental 
health indicators over time in patients currently on efavirenz, as well as ongoing monitoring 
of neuropsychiatric side effects for patients on efavirenz, or other agents, in developing 
world, in order to ensure access to safe, tolerable ART regimens for all people living with 
HIV.
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Proportion of 8,230 HIV-infected Adults Initiating Efavirenz-containing ART as First Line 
Therapy from 1999 to 2015 in CNICS: A) Overall and B) by Prior Mental Health Diagnosis 
(Dx).
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Time from ART initiation to initial regimen switch among 8,230 new ART users, stratified 
by initial ART regimen. ART regimen switch is defined as switching to an efavirenz-
containing or efavirenz-free regimen, depending on initial ART regimen (log-rang p-value 
<0.01.).
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Table 1




 EFV-free ART 4,520 (54.9)
 EFV-containing ART 3,710 (45.1)
Prior mono or dual ARV use
 No 7,837 (95.2)
 Yes 393 (4.8)
Year initiated cART
 1999–2006 3,310 (40.2)
 2007–2011 2,532 (30.8)
 2012–2015 2,388 (29.0)
Age, median (IQR) 38 (30, 45)
Gender
 Male 6,791 (82.5)
 Female 1,439 (17.5)
Race/ethnicity
 White, non-Hispanic 3,599 (44.2)
 Black, non-Hispanic 2,961 (36.3)
 Hispanic 1,148 (14.1)
 Other 452 (5.5)
HIV risk group
 MSM 4,616 (57.0)
 IDU 1,295 (16.0)
 Heterosexual 2,066 (25.5)
 Other 129 (1.6)
Antidepressant use
 Not on antidepressants 6,958 (84.5)
 On antidepressants 1,272 (15.5)
Previous mental health diagnosis2
 No 6,146 (74.7)
 Yes 2,084 (25.3)
Previous medical diagnosis3
 No 7,214 (87.7)
 Yes 1,016 (12.4)
CD4 count, cells/mm3
 ≤ 350 5,532 (68.0)
 > 350 2,599 (32.0)
Missing data: race/ethnicity n=70 (0.9%), HIV risk group n=124 (1.5%), CD4 count n=99 (1.2%).
1
Defined as switching to an efavirenz-containing or efavirenz-free regimen, depending on initial ART regimen.
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2
Defined as a clinician-documented diagnosis of depression, bipolar disorder, post-traumatic stress disorder or psychosis in a participant’s medical 
chart.
3
Defined as clinician-documented diagnosis of hypertension or diabetes.
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Table 2
Baseline correlates of initiating EFV-containing ART, among 8,230 new ART users in CNICS.
Baseline Characteristics
Bivariable Multivariable1
PR (95% CI) p-value PR (95% CI) p-value
Prior mono or dual ARV use
 No 1.00 1.00
 Yes 0.81 (0.71, 0.93) <0.01 0.78 (0.68, 0.89) <0.01
Year initiated ART
 1995–2006 1.00 1.00
 2007–2015 0.91 (0.87, 0.96) <0.01 0.95 (0.90, 0.99) 0.03
Age, per year 1.00 (1.00, 1.00) 0.95 -- --
Gender
 Male 1.00 1.00
 Female 0.77 (0.72, 0.83) <0.01 0.80 (0.74, 0.87) <0.01
Race/ethnicity
 White, non-Hispanic or other 1.00 -- --
  Black, non-Hispanic 1.00 (0.94, 1.05) 0.88 -- --
 Hispanic 1.04 (0.97, 1.12) 0.26 -- --
HIV risk group
 MSM or Other 1.00 1.00
 IDU 0.80 (0.75, 0.87) <0.01 0.85 (0.79, 0.92) <0.01
 Heterosexual 0.88 (0.83, 0.93) <0.01 0.96 (0.89, 1.03) 0.24
Antidepressant use
 No on antidepressants 1.00 1.00
 On antidepressants 0.82 (0.76, 0.88) <0.01 0.91 (0.84, 0.98) 0.02
Previous mental health diagnosis
 No 1.00 1.00
 Yes 0.76 (0.71, 0.81) <0.01 0.80 (0.75, 0.86) <0.01
Previous medical diagnosis
 No 1.00 -- --
 Yes 0.94 (0.87, 1.02) 0.13 -- --
CD4 count, cells/mm3
 ≤ 350 1.00 1.00
 >350 0.92 (0.87, 0.97) <0.01 0.94 (0.89, 0.99) 0.03
1
Model adjusted for all variables in the table and additionally adjusted for site.
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Table 3




HR (95% CI) p-value HR (95% CI) p-value
Prior mono or dual ARV use
 No 1.00 -- --
 Yes 1.07 (0.73, 1.61) 0.73 -- --
Year initiated ART
 1999–2006 1.00 1.00
 2007–2011 1.64 (1.36, 1.98) <0.01 1.70 (1.40, 2.05) <0.01
 2012–2015 3.24 (2.59, 4.05) <0.01 3.68 (2.93, 4.62) <0.01
Age, per year 0.99 (0.99, 1.00) 0.14 -- --
Gender
 Male 1.00 -- --
 Female 1.16 (0.94, 1.44) 0.16 -- --
Race/ethnicity
 White, non-Hispanic or Other 1.00 1.00
 Black, non-Hispanic 1.15 (0.98, 1.36) 0.09 1.08 (0.90, 1.29) 0.40
 Hispanic 0.97 (0.78, 1.22) 0.82 1.00 (0.79, 1.26) 0.99
HIV risk group
 MSM or Other 1.00 -- --
 IDU 1.03 (0.80, 1.31) 0.83 -- --
 Heterosexual 1.03 (0.87, 1.23) 0.71 -- --
Antidepressant use
 No on antidepressants 1.00 -- --
 On antidepressants 1.09 (0.88, 1.34) 0.45 -- --
Previous mental health diagnosis
 No 1.00 1.00
 Yes 1.33 (1.12, 1.59) <0.01 1.33 (1.11, 1.59) <0.01
Previous medical diagnosis
 No 1.00 -- --
 Yes 1.08 (0.86, 1.34) 0.51 -- --
CD4 count, cells/mm3
 ≤ 350 1.00 -- --
 >350 1.07 (0.91, 1.27) 0.41 -- --
1
Model adjusted for all variables in the table and site.
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